412P - The evaluation of chromosomal changes in patients with osteosarcoma

Background

To study of cytogenetic changes in peripheral blood lymphocytes of patients with osteosarcoma.

Methods

Studies were conducted in peripheral blood samples of 196 patients with osteosarcoma (OS) aged from 10 to 45 years. The primary cytogenetic study of patients was carried out before their clinical examination.

Results

The analysis showed that after chemotherapy, 59.5% of patients had a full and partial effect. At 46.2%, the background level of chromosomal abnormalities was less than 5% (discriminatory or dividing level), but 2.5 times higher than the average level of chromosomal abnormalities in healthy individuals. The lack of effect was observed in 40.5% of patients, and their background chromosomal abnormalities were higher than discriminatory (5%) and 7.5 times higher than in healthy individuals. A comparative analysis of the effectiveness of the treatment and the average background level of Cr-disorders among patients in this group showed that 46.2% of patients with a positive effect from chemotherapy had an average level of Cr-disorders in peripheral blood lymphocytes 2.4 times lower, than in patients with a lack of effect from this therapy.

Conclusions

The analysis showed that in the absence of the effect of the treatment carried out, the background indicators of chromosomal aberrations are significantly higher than in healthy individuals or in individuals with good clinical effect. Consequently, according to the level of chromosome aberrations in the peripheral blood lymphocytes of patients with OS identified before the start of treatment, the therapeutic effect can be predicted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Ronc.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.